Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
13.16
-1.03 (-7.26%)
At close: Sep 15, 2025, 4:00 PM EDT
13.31
+0.15 (1.14%)
After-hours: Sep 15, 2025, 7:50 PM EDT
Denali Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts that cover Denali Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $33.62, which forecasts a 155.47% increase in the stock price over the next year. The lowest target is $24 and the highest is $45.
Price Target: $33.62 (+155.47%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Denali Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 7 | 7 | 7 | 7 | 7 |
| Buy | 7 | 7 | 7 | 7 | 7 | 8 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 15 | 15 | 15 | 15 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 8, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $33 → $30 | Buy | Maintains | $33 → $30 | +127.96% | Aug 18, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $28 → $27 | Strong Buy | Maintains | $28 → $27 | +105.17% | May 19, 2025 |
| Baird | Baird | Buy Maintains $30 → $29 | Buy | Maintains | $30 → $29 | +120.36% | May 8, 2025 |
| Wedbush | Wedbush | Buy Maintains $32 → $30 | Buy | Maintains | $32 → $30 | +127.96% | May 7, 2025 |
Financial Forecast
Revenue This Year
72.86K
Revenue Next Year
69.63M
from 72.86K
Increased by 95,463.19%
EPS This Year
-3.09
from -2.57
EPS Next Year
-3.02
from -3.09
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.1M | 181.5M | |||
| Avg | 72,859 | 69.6M | |||
| Low | n/a | 9.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 249,026.4% | |||
| Avg | - | 95,463.2% | |||
| Low | - | 12,761.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.77 | -2.36 | |||
| Avg | -3.09 | -3.02 | |||
| Low | -3.23 | -3.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.